Three cancer drugs will be produced in the UAE in Mubadala Bio's new facility, marking a major step in "enhancing drug security and availability of cost-effective treatment options for patients" in the country.
The facility will produce Lenalidomide – to treat myeloma (a type of blood cancer); Pomalidomide – locally produced for the first time in the UAE, used to treat multiple myeloma; and Sunitinib – a targeted therapy used to treat certain types of advanced or progressive cancers.
Located at its subsidiary, Bioventure Healthcare, the facility is designed to handle high-potency drugs, including oncology and hormone products and is constructed to meet the highest international safety and regulatory standards.
"This milestone supports the development of a stronger and more advanced life sciences industry in the country while delivering meaningful benefits to healthcare providers and patients through improved access to critical treatments," highlighted Dr. Bakheet Al Katheeri, CEO of Mubadala's UAE Investments Platform and Chairman of Mubadala Bio.
Dr. Essam Mohamed, CEO of Mubadala Bio, said, “By investing in local capabilities and launching essential oncology medications, we are expanding access to additional medical therapies and ensuring consistent supply locally."
It's part of Mubadala Bio’s broader strategy to enhance national drug security and ensure a consistent supply of essential treatments.
UAE, Russian Presidents discuss ties, regional developments
UAE begins loading humanitarian vessel bound for Gaza
Italian president praises Zayed Award honour for Armenia, Azerbaijan
Dubai opens major Al Qudra bridge to cut travel time by over 50%
